Hopefully Prof. de Souza can get the screening process underway quickly. Does anyone know what criteria they are using for patient selection, other than the broad trial abstract for IONIC-1 i haven't been able to find clinical trial info online?
Papers like the one below have me excited to see if Veyonda can have a positive impact.
Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1 | Nature Communications
- Forums
- ASX - By Stock
- NOX
- Impact of COVID-19 on clinical trials
Impact of COVID-19 on clinical trials, page-14
-
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
|
|||||
Last
6.9¢ |
Change
-0.003(4.17%) |
Mkt cap ! $20.16M |
Open | High | Low | Value | Volume |
6.9¢ | 6.9¢ | 6.9¢ | $310 | 4.492K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 67971 | 6.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.2¢ | 8810 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 67971 | 0.069 |
2 | 14000 | 0.068 |
1 | 1672 | 0.066 |
1 | 15000 | 0.065 |
1 | 79000 | 0.063 |
Price($) | Vol. | No. |
---|---|---|
0.072 | 8810 | 1 |
0.074 | 50000 | 1 |
0.076 | 4999 | 1 |
0.079 | 12000 | 1 |
0.080 | 100000 | 1 |
Last trade - 14.16pm 29/07/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |